$CVRx Inc (CVRX.US)$ CVRx Reports Third Quarter 2024 Financial and Operating Results Positive ▪️Revenue growth of 27% YoY to $13.4 million ▪️U.S. Heart Failure revenue increased 30% to $12.2 million ▪️Active implanting centers grew 31% to 208 ▪️Hospital reimbursement increased from $17-23K to $43K per procedure ▪️Secured Category I CPT codes for improved reimbursement ▪️Strong cash position of $100.2 million ▪️Gross margin maintained at 83% Negative ▪️Net loss increased to $13.1 mil...
1
1
Report
HailTheApocalypse
:
should go up 1 to 2 dollars and 60 cents a share according to some analysts. might have to get me some. virtually that is lol.
$CVRx Inc (CVRX.US)$ CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim CVRx, Inc. (NASDAQ: CVRX) has announced the publication of new data in JACC: Heart Failure, showcasing the long-term quality of life benefits of Barostim for heart failure patients with reduced ejection fraction. The data, from the BeAT-HF trial, demonstrates durable improvements up to 24 months in Minnesota Living with Heart Failure (MLWHF) and EuroQual-5D (EQ-5D) quality of lif...
The board is excited about Hykes' appointment due to his experience and track record. Hykes is enthusiastic about his new CEO role and plans to leverage the team's momentum for further success.
CVRx Inc Stock Forum
CVRx Reports Third Quarter 2024 Financial and Operating Results
Positive
▪️Revenue growth of 27% YoY to $13.4 million
▪️U.S. Heart Failure revenue increased 30% to $12.2 million
▪️Active implanting centers grew 31% to 208
▪️Hospital reimbursement increased from $17-23K to $43K per procedure
▪️Secured Category I CPT codes for improved reimbursement
▪️Strong cash position of $100.2 million
▪️Gross margin maintained at 83%
Negative
▪️Net loss increased to $13.1 mil...
CVRx Inc | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Johnson & Johnson(17.0%),Johnson & Johnson Innovation-JJDC, Inc.(17.0%)
📊⚡️📊
CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
CVRx, Inc. (NASDAQ: CVRX) has announced the publication of new data in JACC: Heart Failure, showcasing the long-term quality of life benefits of Barostim for heart failure patients with reduced ejection fraction. The data, from the BeAT-HF trial, demonstrates durable improvements up to 24 months in Minnesota Living with Heart Failure (MLWHF) and EuroQual-5D (EQ-5D) quality of lif...
No comment yet